Cardiac Failure

  • A. Ross Lorimer
  • W. Stewart Hillis
Part of the Treatment in Clinical Medicine book series (TC MEDICINE)

Abstract

The clinical syndrome of cardiac failure has long been recognised, but its management remains one of the major problems in clinical cardiology. About one-quarter of patients with cardiovascular disease have heart failure and the long-term prognosis is determined by the degree to which cardiac performance is impaired (Klainer et al. 1965). Recent innovations in the investigation of cardiac patients have increased our understanding of the mechanism of cardiac failure and aided the development of a logical approach to its long-term management.

Keywords

Angiotensin Cardiomyopathy Catecholamine Cardiol Theophylline 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armstrong PW, Armstrong JA, Marks GS (1980) Pharmacokinetic-haemodynamic studies of nitroglycerin ointment in congestive heart failure. Am J Cardiol 46: 670–676PubMedCrossRefGoogle Scholar
  2. Arnold SB, Byrd RC, Meister W et al. (1980) Long-term digitalis therapy in left ventricular function in heart failure. N Engl J Med 303:1443–1448PubMedCrossRefGoogle Scholar
  3. Awan NA, Miller R, De Maria AN, Maxwell KS, Newmann A, Mason DT (1977) Efficacy of ambulatory systemic vasodilator therapy with oral Prazosin in chronic refractory heart failure. Circulation 56: 346–354PubMedGoogle Scholar
  4. Bourdillon PDV, Dawson JR, Foale RA, Timmis AD, Poole-Wilson PS, Sutton GC (1980) Salbutamol in treatment of heart failure. Br Heart J 43: 206–210PubMedCrossRefGoogle Scholar
  5. Chatterjee K, Parmley WW, Massie B et al. (1976) Oral hydralazine therapy for chronic refractory heart failure, Circulation 54: 879–883PubMedGoogle Scholar
  6. Chatterjee K, Massie B, Rubin S et al. (1978) Long-term outpatient vasodilation therapy of congestive heart failure: consideration of agents at rest and during exercise. Am J Med 65: 134–145PubMedCrossRefGoogle Scholar
  7. Cohn JN, Franciosa JA (1977) Vasodilator therapy of cardiac failure. N Engl J Med 297:27–31; 254–258PubMedCrossRefGoogle Scholar
  8. Davis JO, Freeman RH (1976) Mechanisms regulating renin release. Physiol Review 56: 1–56Google Scholar
  9. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJC (1973) Renal and extrarenal haemodynamic effects of furosemide in congestive heart failure after myocardial infarction. N Engl J Med 288: 1087–1090PubMedCrossRefGoogle Scholar
  10. Erdmann E, Brown L (1983) The cardiac glycoside-receptor system in the human heart. Eur Heart J 4 (Supple A): 61–65PubMedGoogle Scholar
  11. Fabiato A, Fabiato F (1979) Calcium and cardiac excitation-contraction coupling. Ann Rev Physiol 41: 473–484CrossRefGoogle Scholar
  12. Firth BG, Delmar CJ, Corbett JR, Lewis SE, Parkey RW, Willerson JT (1980) Effect of chronic oral digoxin therapy on ventricular function at rest and peak exercise in patients with ischaemic heart disease. Am J Cardiol 46: 481–490PubMedCrossRefGoogle Scholar
  13. Hillis WS, Been M (1982) Phosphodiesterase inhibitors, haemodynamic effects related to the treatment of cardiac failure. Eur Heart J 3: 97–103PubMedGoogle Scholar
  14. Hutton I, Murray RG, Boyes RN, Rae AP, Hillis WS (1980) Haemodynamic effects of prenalterol in patients with coronary heart disease Br Heart J 43: 134–137PubMedCrossRefGoogle Scholar
  15. Katz AM, Smith VE (1982) Regulation of myocardial function in the normal and diseased heart: modification by inotropic drugs. Eur Heart J 3 (Suppl): 11–19PubMedGoogle Scholar
  16. Klainer LM, Gibson TC, White KL (1965) The epidemiology of cardiac failure. J Chron Dis 18: 797–814PubMedCrossRefGoogle Scholar
  17. Kleimann JH, Ingels NB, Daughters G, Stinson EB, Alderman EL, Goldmann RH (1978) Left ventricular dynamics during long-term digoxin treatment in patients with stable coronary artery disease. Am J Cardiol 41: 937–943CrossRefGoogle Scholar
  18. Klein W, Brandt D, Maurer E (1981) Haemodynamic assessment of prenalterol: a cardioselective beta-agonist in patients with impaired left ventricular function. Clin Cardiol 94: 325–329Google Scholar
  19. Lal S, Murtagh JG, Pollock AM, Fletcher E, Binnion PF (1969) Acute haemodynamic effects of frusemide in patients with normal and raised left atrial pressure. Br Heart J 31: 711–717PubMedCrossRefGoogle Scholar
  20. Levine TB, Franciosa JA, Cohn JN (1980) Acute and long-term response to an oral converting enzyme inhibitor Captopril, in congestive heart failure. Circulation 62: 35–41PubMedGoogle Scholar
  21. Malliani A (1982) Cardiovascular sympathetic afferent fibres. Rev Physiol Biochem Pharmacol 94: 11–74CrossRefGoogle Scholar
  22. Mason DT (1967) Control of peripheral circulation in health and disease. Mod Concepts Cardiovasc Dis 36: 25–28Google Scholar
  23. Massie B, Ports T, Chatterjee K (1981) Long-term vasodilator therapy for heart failure: clinical response and its relationship to haemodynamic measurements. Circulation 63: 269–278PubMedCrossRefGoogle Scholar
  24. Mathey D (1980) Hydralazine in chronic left heart failure. Cardiology 65: 55–57PubMedCrossRefGoogle Scholar
  25. Miller RR, Williams DO, Mason DT (1976a) Pharmacological mechanisms for LV unloading in clinical congestive heart failure: differential effects of nitroprusside, phentolamine and nitroglycerin on cardiac function and peripheral circulation. Circ Res 39: 127–133PubMedGoogle Scholar
  26. Miller RR, Vismara LA, Williams DO, Amsterdam EA, Mason DT (1976b) Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Circ Res 39:127-133PubMedGoogle Scholar
  27. Mills CJ, Cabe IJ, Mason DT (1970) Pressure flow relationships and vascular impedance in man. Cardio vase Res 4: 405–417CrossRefGoogle Scholar
  28. Nellis SH, Flaim SF, McCauley K, Zelis R (1980) Alpha-stimulation protects exercise increment in skeletal muscle oxygen consumption. Am J Physiol 238: 331–339Google Scholar
  29. Nelson GIC, Silke B, Ahuja RC, Taylor SH (1982a) Arterial dilatation or venodilatation following frusemide in acute heart failure following myocardial infarction. Clin Sci 63: 3PGoogle Scholar
  30. Nelson GIC, Silke B, Barker MCJ, Saxton CAPD, Taylor SH (1982b) A new beta-2 adrenoceptor agonist (pirbuterol) in the treatment of ischaemic heart failure. Eur Heart J 3: 238–245PubMedGoogle Scholar
  31. Nicholls MG, Espiner EA, Donald RA, Hughes H (1974) Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med 47: 301–315PubMedGoogle Scholar
  32. O’Rourke RA, Hening H, Theroux P, Crawford MH, Ross J Jr (1976) Favourable effect of orally adminstered digoxin on left heart size and ventricular wall motion in patients with previous myocardial infarction. Am J Cardiol 37: 708–716PubMedCrossRefGoogle Scholar
  33. Packer M, Meller J, Gorlin R, Herman MV (1979) Haemodynamic and clinical tachyphylaxis to prazosin mediated afterload reduction in severe chronic congestive heart failure. Circulation 59: 531–539PubMedGoogle Scholar
  34. Scholz H (1983) Pharmacological actions of various inotropic drugs Eur Heart J 4: 161–173PubMedGoogle Scholar
  35. Sharpe DN, Douglas JE, Coxon RJ, Long B (1980) Low dose Captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet II: 1154–1157CrossRefGoogle Scholar
  36. Silke B, Hendry WG, Taylor SH (1981) Immediate and sustained haemodynamic effects of prazosin during upright exercise in man. Br Heart J 46: 663–670PubMedCrossRefGoogle Scholar
  37. Skou JC (1957) The influence of some cations on an adenosine triphosphate from peripheral nerves. Biochem Biophys Acta 23: 349–401CrossRefGoogle Scholar
  38. Sonnenblick EH, Le Jemtel TH (1982) Newer inotropic agents in congestive heart failure. In: Braunwald E, Mokk MB, Watson J (eds) Congestive heart failure, current research and clinical applications. Grune-Stratton, New York, pp 291–302Google Scholar
  39. Sonnenblick EH, Spiro D, Spotnitz HM (1964) Ultrastructural basis of Starling’s law of the heart; role of sarcomere in determining ventricular size and stroke volume. Am Heart J 68: 336–346PubMedCrossRefGoogle Scholar
  40. Spann JF, Buccino RA, Sonnenblick EA (1967) Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res 21: 341–354PubMedGoogle Scholar
  41. Taylor SA, Silke B, Nelson GK (1982) Principles of treatment of left ventricular failure. Eur Heart J 3: 19–43PubMedGoogle Scholar
  42. Watkins L Jr, Burton JA, Cant JR, Smith FW, Barger AC (1976) The renin angiotensin aldosterone system in congestive failure in conscious dogs. J Clin Invest 57: 1606–1617PubMedCrossRefGoogle Scholar
  43. Wikman-Coffelt J, Parmley WW, Mason DT (1979) The cardiac hypertrophy process: analysis of factors determining pathological v physiological development. Circ Res 45: 697–707PubMedGoogle Scholar
  44. Zelis R, Mason DT, Braunwald E (1968) A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J Clin Invest 47: 960–970PubMedCrossRefGoogle Scholar
  45. Zelis R, Delea CS, Comeman et al. (1970) Arterial sodium content in experimental congestive heart failure. Circulation 41: 213–216PubMedGoogle Scholar
  46. Zelis R, Flaim SF (1982) Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis 24: 437–459PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • A. Ross Lorimer
    • 1
  • W. Stewart Hillis
    • 2
  1. 1.Royal InfirmaryGlasgowScotland, UK
  2. 2.Stobhill General HospitalGlasgowScotland, UK

Personalised recommendations